What exactly did Jefferies change on March 13, 2026?

Jefferies maintained a **Hold** rating for Mineralys Therapeutics, Inc. and lowered the price target to **$30**. This maintained stance is recorded as the current MLYS analyst rating and reflects a cautious near-term view.

How did the stock react to the Jefferies update?

The update coincided with a **-2.75% ($-0.74)** move in the news feed. Short-term volatility followed the price target cut as investors digested the maintained Hold view.

What does a Hold rating mean for my investment strategy?

A Hold rating typically means limited expected upside in the near term. Investors should weigh cash flow, clinical timelines, and price targets before changing a long-term position.

Where can I read the analyst note and related coverage?

See the Jefferies brief on StreetInsider for the full note [source](https://www.streetinsider.com/Analyst+Comments/Mineralys+Therapeutics%2C+Inc.+%28MLYS%29+PT+Lowered+to+%2430+at+Jefferies/26158308.html). For broader rating trends check recent headlines on Investing.com [source](https://www.investi

Analyst Ratings

Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026

ByDanny Kontos March 14, 2026March 14, 2026

Jefferies maintained a Hold rating on Mineralys Therapeutics, Inc. (MLYS) on March 13, 2026. This MLYS analyst rating included a price target cut to $30, cited in the Jefferies note. The StreetInsider report shows the update and a short-term market reaction. Investors should note the note also recorded a -2.75% ($-0.74) price change at the time of the bulletin. We use Meyka AI data to frame the implications for holders and traders.